Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

What was studied

This review pooled trials of enlicitide, a pill that blocks PCSK9. It looked at adults with high cholesterol. The review pooled randomized trials. The trials compared the drug with placebo. They covered 3593 people in all. The main measure was the change in LDL cholesterol. The team also checked other blood fats and safety.

What they found

LDL cholesterol fell more with enlicitide than with placebo. Other blood fats also fell, including ApoB, lipoprotein(a) and triglycerides. Effects looked larger at higher doses. But the dose differences were not statistically significant. Side effects, serious side effects and stopping treatment were similar between groups.

What it means for patients

The authors say enlicitide led to large drops in LDL cholesterol and other blood fats. They say side effects did not clearly rise. They say the findings need cautious reading. They say long-term heart outcome trials are needed to show clinical benefit.

Why it is not certain yet

The review had a limited number of trials. This is a meta-analysis of randomized trials. Results varied moderately between trials. The trials measured blood tests rather than heart outcomes. The dose findings were exploratory. Single trials drove some findings.

Source

Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

We restate facts from the source record in our own words. The original wording belongs to its publisher.